Evaluation of 177Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors

doi:10.3748/wjg.v26.i13.1513

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7909)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

670

WORD

271

HTML

4563

Figures (1-4)

283

Tables (1-1)

316

Sum=6103

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

592

Download

1214

Sum=1806

Apr 7, 2020 (publication date) through Jul 26, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Apr 7, 2020; 26(13): 1513-1524
Published online Apr 7, 2020. doi: 10.3748/wjg.v26.i13.1513

Full Size Figure Download Figure

Figure 1 Graphical representation of overall survival in patients diagnosed with neuroendocrine tumors treated with peptide receptor radionuclide therapy. A median survival of 12.5 mo is shown (95% confidence interval: 9.8–15.2).

Citation: Abou Jokh Casas E, Pubul Núñez V, Anido-Herranz U, del Carmen Mallón Araujo M, del Carmen Pombo Pasín M, Garrido Pumar M, Cabezas Agrícola JM, Cameselle-Teijeiro JM, Hilal A, Ruibal Morell Á. Evaluation of ¹⁷⁷Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors. World J Gastroenterol 2020; 26(13): 1513-1524
URL: https://www.wjgnet.com/1007-9327/full/v26/i13/1513.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i13.1513